Yum! Brands, Inc. (NYSE:YUM) [Trend Analysis] climbed reacts as active mover, shares a gain 0.17% to traded at $82.59 and the percentage gap between open changing to regular change was 0.10%. Yum! Brands subs commence offering of $2.3 biliion aggregate principal amount of Senior Unsecured Notes in two tranches, with maturities in 2024 and 2026. The Notes will be guaranteed on a senior unsecured basis by the Company and the Company’s domestic subsidiaries that will guarantee its previously announced new Senior Secured Credit Facility.
Net proceeds from the offering of the Notes, together with the proceeds from the Senior Secured Credit Facility, will be used to fund a return of capital to shareholders, repay borrowings under the Company’s existing revolving credit facility, pay associated transaction fees and expenses, and for general corporate purposes.
Net proceeds from the offering of the Notes, together with the proceeds from the Senior Secured Credit Facility, will be used to fund a return of capital to shareholders, repay borrowings under the Company’s existing revolving credit facility, pay associated transaction fees and expenses, and for general corporate purposes. The firm’s current ratio calculated as 0.40 for the most recent quarter. The firm past twelve months price to sales ratio was 2.56. As far as the returns are concern, the return on equity was recorded as 118.50% and return on investment was 29.40% while its return on asset stayed at 16.10%. The firm has total debt to equity ratio measured as 30.97.
Titan Pharmaceuticals Inc. (NASDAQ:TTNP) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -2.97% to close at $6.86 with the total traded volume of 9.42 Million shares. Titan Pharmaceuticals, Inc. (TTNP) revealed that U.S. FDA has permitted Probuphine or buprenorphine implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine.
The Probuphine subdermal implant, which utilizes Titan’s proprietary ProNeuratechnology, delivers buprenorphine continuously for up to six months. The product is expected to be commercially available this summer and is recommended for use as part of a complete treatment program including counseling and psychosocial support. The firm has institutional ownership of 3.50%, while insider ownership included 1.40%. Its price to sales ratio ended at 177.50. TTNP attains analyst recommendation of 2.00 with week performance of 8.20%.
Tyco International plc (NYSE:TYC) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 0.12% to $42.68. Johnson Controls and Tyco International (TYC) detailed plans for executive team to lead the combined company following the close of merger (expected on or around Oct. 1, 2016) (JCI).
Tyco chief executive officer George Oliver will serve as president and chief operating officer, with responsibility for the operating businesses and leading the integration, and will become a director on the new company’s board. Molinaroli will serve as chairman and chief executive officer for 18 months after the closing. At that time, Oliver will become chief executive officer and Molinaroli will become executive chair for one year, after which Mr. Oliver will become chairman and chief executive officer. The share price of TYC attracts active investors, as stock price of week volatility recorded 1.51%. The stock is going forward to its 52-week low with 48.31% and lagging behind from its 52-week high price with -0.88%.